Counterfactual Thinking in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis Clinical Trial

— CFTSLA  

Official title:

Counterfactual Thinking Assessment in Amyotrophic Lateral Sclerosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05768646
• Other study ID #: 23C122
• Status: Recruiting
• Start date: March 31, 2021
• Est. completion date: September 30, 2023

Study information

• Verified date: March 2023
• Source: Istituto Auxologico Italiano
• Contact: Barbara Poletti, Ph.D.
• Phone: +0261911
• Email: b.poletti[@]auxologico.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The properness of our past choices and action is usually judged according to what could have been if we had behaved differently. This ability to simulate alternatives to past factual events and actions is called counterfactual thinking (CFT) and is closely related to the decision-making process and future behaviors. In fact, the generation of CFT fulfills an important preparatory function, since it offers behavioral instructions that can guide the individual in facing similar decision-making problems in the future. Consequently, a damage or a reduction in the CFT are likely to impact on the individual's decision-making (DM) ability, especially regarding crucial decisions such as those in the medical field. In recent years, growing evidence has highlighted alterations in CFT in several neurological, neurodegenerative and psychiatric conditions, such as Huntington's disease, Parkinson's disease, prefrontal cortex damage, schizophrenia, obsessive-compulsive disorder and major depressive disorder, underlining how CFT deficits are specifically associated with frontal-executive dysfunction. These alterations, as mentioned, can lead to non-optimal DM processes and behaviors.

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of motor neurons in the spinal cord, brain stem and motor cortex. Literature data have highlighted the presence of cognitive and behavioral alterations as integral parts of the disease, as a part of a continuum, with a partial overlap, between ALS and frontotemporal dementia (FTD). The progressive and fatal course of the disease and the presence of cognitive/behavioral alterations, together with the impairment in communication skills, have significant implications on patient's competence in the advance care planning, especially regarding informed consent to advance treatment and end-of-life decision. In particular, patients' perspectives about therapeutic choices and end-of-life interventions are likely to be influenced by cognitive-behavioral aspects, where the integrity of frontal-executive functions plays a crucial role in patients' DM ability.

The investigators hypothesize that ALS patients will show a certain deficit in CFT, both in the ability to generate counterfactual thoughts related to a negative real-life and in the ability to use CFT to make causal inferences in fictional social scenarios. Moreover, a relationship between CFT and DM abilities is expected to be found. These expected impairments are likely to be associated with the cognitive and behavioral alterations that typically occur in ALS.

Primary aim The primary purpose of the study is to investigate the integrity of CFT ability in patients with ALS.

Specifically, this study aims to: (1) evaluate the functioning of the CFT in a group of patients affected by ALS; (2) investigate how the functioning of the CFT is associated with the ALS typical cognitive-behavioral alterations; (3) evaluate the possible association between CFT and DM abilities; (4) investigate how clinical, psychological, cognitive and behavioral variables affect CFT integrity.

Secondary aim CFT ability will be investigated along the course of the disease, with patients being recruited in a longitudinal study. When possible, according to clinical conditions, patients will be assessed at 0-6-12-24 months, in order to better characterize CFT and DM functioning over time, as well as patients' cognitive-behavioral profile. .

We expect to highlight a deficit or a reduction in patients' CFT ability and such alteration is likely to be associated with DM skills, as well as with the specific cognitive and behavioral profile of ALS patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 157
• Est. completion date: September 30, 2023
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients: probable or definite ALS

• Healthy controls: not applicable

Exclusion Criteria:

• Patients: other brain disorders; severe general medical conditions and uncorrected visual/hearing deficits

• Healthy controls: brain disorders; severe general medical conditions and uncorrected visual/hearing deficits

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Behavioral:
• Neuropsychological instruments
Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features

Locations

Country	Name	City	State
Italy	Istituto Auxologico Italiano	Milan

Sponsors (1)

Lead Sponsor	Collaborator
Istituto Auxologico Italiano

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Counterfactual Inference Test	Performance-based tests assessing the ability to use CFT in order to make inferences	At enrollment
Primary	Spontaneous Counterfactual Generation Test	Performance-based tests assessing CFT abilities, in particular the frequency of CFT generated in response to a personal, real-life event.	At enrollment
Secondary	Longitudinal assessment of CFT abilities	Performance-based tests assessing the ability to use CFT in order to make inferences (i.e. Counterfactual Inference Test) and the frequency of CFT generated in response to a personal, real-life event (i.e., Spontaneous Counterfactual Generation Test) will be administered along the course of the disease, with patients being recruited in a longitudinal study. When possible, according to clinical conditions, patients will be assessed at 0-6-12-24 months, in order to better characterize CFT functioning over time.	At enrollment